Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-02 · accession 0001209191-24-002928 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-06 | 2024-02-02 | LXEO | Adler Eric | Chief Medical Off | A - Grant | $0.00 | +26.9K | 26.9K | New | $0 |
| D | 2024-02-06 | 2024-02-02 | LXEO | Adler Eric | Chief Medical Off | A - Grant | $0.00 | +161.2K | 161.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-02 | A | A | 26,875 | $0.00 | 26,875 | D | — | — | (F1) The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-02-02 | A | A | 161,250 | $0.00 | 161,250 | D | $17.00 · — to 2034-02-01 | 161,250 Common Stock | (F2) 25% of the shares underlying the option vest and become exercisable on February 2, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |